Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. One of the major
clinical challenges is adequate diagnosis and treatment of central nervous system (CNS) …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a
main cause of death in children despite recent improvements in cure rates. In the past …

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

Abstract Neurotrophic Tyrosine Receptor Kinase (NTRK) genes undergo chromosomal
translocations to create novel open reading frames coding for oncogenic fusion proteins; the …

Acute myeloid leukemia (AML) is characterized by complex molecular alterations and driver
mutations. Elderly patients show increased frequencies of IDH mutations with high …

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subset of
high-risk B-ALL associated with high relapse risk and inferior clinical outcomes across the …

Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell
precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates …

Emerging studies have highlighted brain-derived neurotrophic factor (BDNF), a neuronal
growth factor abundant in the peripheral blood, and its tyrosine kinase receptor TRKB, as …

Outcomes for patients with relapsed and refractory (R/R) T‐cell acute lymphoblastic
leukemia (T‐ALL) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are …